127 related articles for article (PubMed ID: 27825923)
1. The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib.
Elsadek B; Mansour A; Saleem T; Warnecke A; Kratz F
Dig Liver Dis; 2017 Feb; 49(2):213-222. PubMed ID: 27825923
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.
Fiume L; Bolondi L; Busi C; Chieco P; Kratz F; Lanza M; Mattioli A; Di Stefano G
J Hepatol; 2005 Oct; 43(4):645-52. PubMed ID: 16023760
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug.
Fiume L; Baglioni M; Bolondi L; Farina C; Di Stefano G
Drug Discov Today; 2008 Nov; 13(21-22):1002-9. PubMed ID: 18755287
[TBL] [Abstract][Full Text] [Related]
4. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade.
Di Stefano G; Fiume L; Baglioni M; Bolondi L; Busi C; Chieco P; Kratz F; Manaresi F; Pariali M
Liver Int; 2006 Aug; 26(6):726-33. PubMed ID: 16842330
[TBL] [Abstract][Full Text] [Related]
5. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin.
Di Stefano G; Fiume L; Baglioni M; Busi C; Chieco P; Kratz F; Mattioli A
Eur J Pharm Sci; 2007 Feb; 30(2):136-42. PubMed ID: 17218086
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats.
Di Stefano G; Fiume L; Baglioni M; Busi C; Bolondi L; Farina C; Mori F; Chieco P; Pariali M; Kratz F; Molin L; Salmaso S; Caliceti P
Eur J Pharm Sci; 2008 Feb; 33(2):191-8. PubMed ID: 18201877
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging.
Di Stefano G; Fiume L; Baglioni M; Bolondi L; Chieco P; Kratz F; Pariali M; Rubini G
Dig Liver Dis; 2008 Apr; 40(4):278-84. PubMed ID: 18054847
[TBL] [Abstract][Full Text] [Related]
8. Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Elsayed MM; Mostafa ME; Alaaeldin E; Sarhan HA; Shaykoon MS; Allam S; Ahmed AR; Elsadek BE
Int J Nanomedicine; 2019; 14():8445-8467. PubMed ID: 31754301
[TBL] [Abstract][Full Text] [Related]
9. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
10. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
13. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
[TBL] [Abstract][Full Text] [Related]
15. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
16. Liver-targeted doxorubicin: effects on rat regenerating hepatocytes.
Di Stefano G; Derenzini M; Kratz F; Lanza M; Fiume L
Liver Int; 2004 Jun; 24(3):246-52. PubMed ID: 15189276
[TBL] [Abstract][Full Text] [Related]
17. [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Shinohara M; Kikuchi Y; Igarashi Y; Sumino Y
Gan To Kagaku Ryoho; 2016 Jul; 43(7):863-7. PubMed ID: 27431630
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
